Stealth Biotherapeutics Inc. has presented new data demonstrating cardioprotective effects of SBT-589 in preclinical models of Friedreich’s ataxia (FA). SBT-589 acts on mitochondrial pathways essential for cellular health and energy production that are impaired in FA cardiomyopathy.
Previous research found that p62 is the key autophagy adapter protein and a hub of multicellular signaling involved in different physiological and pathological processes.
Researchers from the Center of Biomedical Research (Lucknow) presented data from a study that assessed the functional significance the translocation of the regulator of G protein signaling 6 (RGS6) to the nucleus in response to cytotoxic stress.
Heart failure with preserved ejection fraction (HFpEF) has limited treatment options and remains a medical challenge. HFpEF is characterized by diastolic dysfunction with a normal ejection fraction. Previous findings have shown that inhibiting histone deacetylase 6 (HDAC6) alters the mechanisms contributing to dilated cardiomyopathy.
Neomorph Inc. has entered into a collaboration and licensing agreement with Novo Nordisk A/S to discover, develop and commercialize molecular glue degraders.
Transthera Sciences (Nanjing) Inc. has announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome inhibitor.
Isomab Ltd has closed a £7.5 million (US$9.4 million) seed financing round. The company is developing isoform-specific disease-modifying antibody treatments for serious and life-threatening diseases with an initial focus on peripheral ischemia.
A team at the Institute of Cellular Biology and Pathology ‘Nicolae Simionescu’ of Romanian Academy aimed to assess the effects of targeted siRNA for AP-1 silencing on restoring structural...
Pulmonary arterial hypertension (PAH) is a severe condition characterized by vasoconstriction and remodeling of the small pulmonary arteries, driven by a complement-dependent activation of macrophages, for which an effective treatment is lacking. Chinese researchers have investigated the potential of a complement C3 inhibitor polypeptide, CP40-KK, as an approach for treating PAH. To do this, they used a model in which PAH was induced in rats by monocrotaline.
Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<
RSS
